Underpowered or negative? A crucial distinction. Reply to Dollerup OL, Treebak JT, Jessen N [letter]

Diabetologia, Apr 2019

Niels J. Connell, Riekelt H. Houtkooper, Patrick Schrauwen

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs00125-019-4868-3.pdf

Underpowered or negative? A crucial distinction. Reply to Dollerup OL, Treebak JT, Jessen N [letter]

Diabetologia pp 1–1 | Cite as Underpowered or negative? A crucial distinction. Reply to Dollerup OL, Treebak JT, Jessen N [letter] AuthorsAuthors and affiliations Niels J. ConnellRiekelt H. HoutkooperPatrick Schrauwen Letter First Online: 13 April 2019 KeywordsClinical trial Human NAD+ metabolism  To the Editor: Jessen and colleagues [1] have commented on our recent review of NAD+ metabolism in Diabetologia [2]. In their letter, they comment on the discussion and citation of a clinical trial that they performed, in which dietary nicotinamide riboside was supplemented in obese men to assess the effects on whole body insulin sensitivity [3]. We concede to the argument made by Jessen and colleagues that it is important to make a clear distinction between endpoints when citing clinical trials, as this may otherwise lead to unwanted assumptions regarding the endpoint(s) that are discussed. In our review, we did not have the intention to suggest that the study by Dollerup et al [3] was underpowered for its primary endpoint, insulin sensitivity, but unfortunately omitted to add ‘for these secondary endpoints’, for which we do apologise. Nevertheless, the overall message and conclusion of our review does not change and we agree with Jessen and colleagues that more human studies are needed to test the efficacy of dietary supplements in rigorously designed human clinical trials. Notes Contribution statement All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published. Duality of interest The authors declare that there is no duality of interest associated with this manuscript. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References 1. Dollerup OL, Treebak JT, Jessen N (2019) Underpowered or negative? A crucial distinction. Diabetologia.  https://doi.org/10.1007/s00125-019-4853-x 2. Connell NJ, Houtkooper RH, Schrauwen P (2019) NAD+ metabolism as a target for metabolic health: have we found the silver bullet? Diabetologia.  https://doi.org/10.1007/s00125-019-4831-3 3. Dollerup OL, Christensen B, Svart M et al (2018) A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 108(2):343–353.  https://doi.org/10.1093/ajcn/nqy132 CrossRefPubMedGoogle Scholar Copyright information © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Authors and Affiliations Niels J. Connell1Riekelt H. Houtkooper2Patrick Schrauwen1Email author1.Department of Nutrition and Movement Sciences, NUTRIM School for Nutrition and Translational Research in MetabolismMaastricht UniversityMaastrichtthe Netherlands2.Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam UMCUniversity of AmsterdamAmsterdamthe Netherlands


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs00125-019-4868-3.pdf

Niels J. Connell, Riekelt H. Houtkooper, Patrick Schrauwen. Underpowered or negative? A crucial distinction. Reply to Dollerup OL, Treebak JT, Jessen N [letter], Diabetologia, 2019, 1-1, DOI: 10.1007/s00125-019-4868-3